Why cognitive variability predicts Alzheimer's decline better than test scores

Cognitive variability measures the fluctuation in your mental performance across days or within a day, rather than just your average score on a single test. Research presented at AAIC 2025 by multiple teams shows APOE4 carriers have significantly more cognitive variability than non-carriers even when traditional testing labels them 'fine.' Dr. Katie Bangen (UC San Diego) tracked 818 people for 3 years and found that for APOE4 carriers specifically, high baseline variability predicted faster decline in real-world functioning (managing money, taking medications, handling complex tasks) before cognitive tests became abnormal. For carriers, variability may be the earliest actionable warning signal available.

Yes, and potentially better than single-visit neuropsych testing. Dr. Andy Aschenbrenner at Washington University used a smartphone app to test people 4 times per day for one week. APOE4 carriers showed more ups and downs across the week, and on days when the app showed worse cognition, people had MORE adverse driving events that same day (more hard braking, speeding, and sudden acceleration) across 20,000+ analyzed car trips. Interestingly, people seemed to implicitly recognize bad days and avoided risky nighttime driving without realizing why. Dr. Andrew Kiselica found variability scores are mostly noise in asymptomatic people but become highly informative once symptoms appear, suggesting smartphone monitoring may be best for the asymptomatic stage when frequent measurement averages out noise.

Variability monitoring costs pennies per day on a smartphone versus roughly $5,000 for an amyloid PET scan or $1,500 for cerebrospinal fluid testing. It requires no invasive procedures, can be done at home, and generates many more data points per year than any clinical biomarker. Dr. Laiss Bertola validated the approach in 9,000+ Brazilians tracked over 8 years, finding that higher cognitive variability at baseline predicted higher odds of impairment 8 years later. For APOE4 carriers who want long-term tracking without repeatedly paying for expensive imaging, variability monitoring via standard neuropsych tests, smartphone apps, and remote cognitive batteries is a high-leverage option.

The mechanism likely reflects the APOE4 brain's reduced metabolic reserve. APOE4 carriers have impaired glucose metabolism in memory-critical regions (20-25 percent lower in the hippocampus), reduced mitochondrial function, and heightened inflammatory responses. On days when sleep, stress, or glucose control are suboptimal, a non-carrier brain has spare capacity and performs normally. An APOE4 carrier brain has less spare capacity, so the same suboptimal day produces a measurable cognitive dip. This also means the variability signal gives carriers something actionable: by tracking which lifestyle factors correlate with their bad days, they can intervene on the specific drivers of their dips rather than chasing generic advice.